Results 21 to 30 of about 910,008 (206)

Multi-Cancer Genome Profiling for Neurotrophic Tropomyosin Receptor Kinase (NTRK) Fusion Genes: Analysis of Profiling Database of 88,688 Tumors. [PDF]

Cancers (Basel)
Simple Summary Neurotrophic tropomyosin receptor kinase (NTRK) genes are known as oncogenic driver genes for various types of cancers. Because the NTRK fusion rate has been reported to be only around 0.2% of all solid tumors, it is necessary to determine
Nishikubo H, Kawabata K, Kanei S, Aoyama R, Ma D, Sano T, Imanishi D, Sakuma T, Maruo K, Fan C, Yamamoto Y, Yashiro M.   +11 more
europepmc   +2 more sources

Dissociation Between Tumor Response and PTTM Progression During Entrectinib Therapy in NTRK Fusion-Positive Colon Cancer. [PDF]

Curr Oncol
Simple Summary We report a rare case of pulmonary tumor thrombotic microangiopathy (PTTM) in a patient with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive colorectal cancer (CRC) who exhibited marked tumor regression with entrectinib ...
Nagano H, Ohyama S, Sato A, Igarashi J, Yamamoto T, Kobayashi M.   +5 more
europepmc   +2 more sources

NTRK Gene Fusion Detection in Atypical Spitz Tumors [PDF]

International Journal of Molecular Sciences, 2021
Atypical Spitz tumors (AST) deviate from stereotypical Spitz nevi for one or more atypical features and are now regarded as an intermediate category of melanocytic tumors with uncertain malignant potential. Activating NTRK1/NTRK3 fusions elicit oncogenic events in Spitz lesions and are targetable with kinase inhibitors.
Rocco Cappellesso, Filippo Nozzoli, Federica Zito Marino, Sara Simi, Francesca Castiglione, Vincenzo De Giorgi, Carlo Cota, Rebecca Senetta, Giosuè Scognamiglio, Anna Maria Anniciello, Anna Maria Cesinaro, Mario Mandalà, Andrea Gianatti, Maria Gabriella Valente, Barbara Valeri, Angela Rita Sementa, Costantino Ricci, Barbara Corti, Giandomenico Roviello, Angelo Paolo Dei Tos, Renato Franco, Daniela Massi   +21 more
openaire   +3 more sources

NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancer. [PDF]

J Cancer Res Clin Oncol, 2023
Pathogenic fusion events involving neurotrophic receptor tyrosine kinase (NTRK) have been described in ~ 2% of differentiated thyroid cancer (DTC).
Koehler VF, Achterfeld J, Sandner N, Koch C, Wiegmann JP, Ivanyi P, Käsmann L, Pusch R, Wolf D, Chirica M, Knösel T, Demes MC, Kumbrink J, Vogl TJ, Meyer G, Spitzweg C, Bojunga J, Kroiss M.   +17 more
europepmc   +2 more sources

Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors. [PDF]

Diagn Pathol, 2020
Abstract Background While ETV6- NTRK3 fusion is common in infantile fibrosarcoma, NTRK1/3 fusion in pediatric tumors is scarce and, consequently, not well known.
Kang J, Park JW, Won JK, Bae JM, Koh J, Yim J, Yun H, Kim SK, Choi JY, Kang HJ, Kim WS, Shin JH, Park SH.   +12 more
europepmc   +6 more sources

BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors. [PDF]

NPJ Precis Oncol
Aberrant activation of tropomyosin receptor kinases (TRKs) is a well-defined oncogenic driver for neurotrophic tropomyosin receptor kinase (NTRK)-fusion cancers, and acquired resistant mutations have emerged with clinical use of the first-generation TRK ...
Sheng J, Chen H, Fu B, Pan H, Wang J, Han W.   +5 more
europepmc   +2 more sources

NTRK fusions are extremely rare in bone tumours [PDF]

Histopathology, 2021
AimsBecause of the efficacy of tropomyosin receptor kinase (Trk) inhibitor therapy in tumours with rearrangements of the neurotrophic tyrosine kinase receptor genes (NRTK genes), there has been a surge in demand for NTRK fusion screening. To date, most studies involving mesenchymal tumours have focused on soft tissue tumours, and data on bone tumours ...
Suk Wai Lam, Inge H Briaire‐de Bruijn, Tom van Wezel, Arjen H G Cleven, Pancras C W Hogendoorn, Anne‐Marie Cleton‐Jansen, Judith V M G Bovée   +6 more
openaire   +4 more sources

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China

npj Precision Oncology, 2023
Neurotrophic tyrosine kinase (NTRK) fusions involving NTRK1, NTRK2, and NTRK3 were found in a broad range of solid tumors as driver gene variants. However, the prevalence of NTRK fusions in Chinese solid tumor patients is rarely reported.
Yujun Xu, Xiaoliang Shi, Weifeng Wang, Lin Zhang, Shinghu Cheung, Marion Rudolph, Nicoletta Brega, Xiaowei Dong, Lili Qian, Liwei Wang, Shaohua Yuan, Daniel Shao Weng Tan, Kai Wang   +12 more
doaj   +1 more source

Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis. [PDF]

Virchows Arch
Thyroid carcinomas exhibit various genetic alterations, including the RET and NTRK fusion genes that are targets for molecular therapies. Thus, detecting fusion genes is crucial for devising effective treatment plans.
Okubo Y, Toda S, Kadoya M, Sato S, Yoshioka E, Hasegawa C, Ono K, Washimi K, Yokose T, Miyagi Y, Masudo K, Iwasaki H, Hayashi H.   +12 more
europepmc   +2 more sources

A review of NTRK fusions in cancer

Annals of Medicine & Surgery, 2022
The family of the neurotrophic tropomyosin kinase receptors (NTRK or TRK) is a part of the transmembrane tyrosine kinases responsible for neuronal development. The members of this receptor family are TRKA, TRKB and TRKC and they are encoded by the genes NTRK1, NTRK2 and NTRK3.
Manea, Cristina Alexandra, Badiu, Dumitru Cristinel, Ploscaru, Ioan Cristian, Zgura, Anca, Bacinschi, Xenia, Smarandache, Catalin Gabriel, Serban, Dragos, Popescu, Cristian Gabriel, Grigorean, Valentin Titus, Botnarciuc, Vladimir   +9 more
openaire   +2 more sources